This is a working overview of Fatty diacid, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
CDP-4-dehydro-6-deoxy-D-glucose + NAD(P)H + H+ The 4 substrates of this enzyme are CDP-4-dehydro-3,6-dideoxy-D-glucose, nicotinamide adenine dinucleotide ion, nicotinamide adenine dinucleotide phosphate ion, and water, whereas its 4 products are CDP-4-dehydro-6-deoxy-D-glucose, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, and hydrogen ion. This enzyme belongs to the family of oxidoreductases, specifically those acting on CH or CH2 groups with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is CDP-4-dehydro-3,6-dideoxy-D-glucose:NAD(P)+ 3-oxidoreductase. Other names in common use include CDP-4-keto-6-deoxyglucose reductase, cytidine diphospho-4-keto-6-deoxy-D-glucose reductase, cytidine diphosphate 4-keto-6-deoxy-D-glucose-3-dehydrogenase, CDP-4-keto-deoxy-glucose reductase, CDP-4-keto-6-deoxy-D-glucose-3-dehydrogenase system, and NAD(P)H:CDP-4-keto-6-deoxy-D-glucose oxidoreductase. This enzyme participates in starch and sucrose metabolism.
== Career == Ciulli remained in Cambridge University to conduct post-doctoral research on fragment-based drug discovery with Professor Abell and Professor Tom L. Blundell, under a College Junior Research Fellowship. Between February and June 2009, Ciulli went to Yale University as Human Frontier Science Programme visiting fellow to visit the laboratory of Professor Craig Crews before returning to Cambridge University to start his independent research career. While at Cambridge, Ciulli was the group leader in the Department of Chemistry, Director of Studies in Chemistry and BBSRC David Phillis Fellow at Christ's College. In April 2013, he took up a Readership in Chemical & Structural Biology as a principal investigator within the Division of Biological Chemistry and Drug Discovery in the University of Dundee. Ciulli was promoted as the Professor of Chemical & Structural Biology in the same division in October 2016. In 2017, he co-founded Amphista Therapeutics, a company that focuses on developing drugs based on targeted protein degradation. He was elected to the Fellowship of the Royal Society of Edinburgh in 2023.
The prognosis for visual restoration and maintenance of ocular health with corneal transplants is generally very good. Risks for failure or guarded prognoses are multifactorial. The type of transplant, the disease state requiring the procedure, the health of the other parts of the recipient eye and even the health of the donor tissue may all confer a more or less favorable prognosis. The majority of corneal transplants result in significant improvement in visual function for many years or a lifetime. In cases of rejection or transplant failure, the surgery can generally be repeated.
Sources: en.wikipedia.org
== Awards and honors == 1936 – Became a member of the United States National Academy of Sciences 1939–1941 – President of the American Society of Biological Chemists 1945–1946 – President of the American Institute of Nutrition 1949 – Osborne and Mendel Award of the American Institute of Nutrition 1952 – Honorary Doctor of Sciences Degree from the University of Illinois 1952 – Willard Gibbs Medal of the American Chemical Society 1957 – Kenneth A. Spencer award of the American Chemical Society 1961 – Twentieth Anniversary Award of the Nutrition Foundation 1966 – Received National Medal of Science 1979 – William C. Rose Award initiated
A 2025 review by the theory's originators sets it against opponent-process theories, habit theories, and theories centered on impaired prefrontal control, and addresses continuing debate over whether craving is central to addiction and whether addictive behavior is accurately described as compulsive. In contrast to ΔFosB's reward-sensitizing effect, CREB transcriptional activity decreases user's sensitivity to the rewarding effects of the substance. CREB transcription in the nucleus accumbens is implicated in psychological dependence and symptoms involving a lack of pleasure or motivation during drug withdrawal.
== External links == mTOR+protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "mTOR Signaling Pathway in Pathway Interaction Database". National Cancer Institute. Archived from the original on 2013-03-18. Retrieved 2015-10-18. Overview of all the structural information available in the PDB for UniProt: P42345 (Serine/threonine-protein kinase mTOR) at the PDBe-KB.
Sources: en.wikipedia.org
Chemotherapy, American Cancer Society Hazardous Drug Exposures in Health Care, National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016, National Institute for Occupational Safety and Health International Ototoxicity Management Group (IOMG) - Wikiversity
For laboratory quantities, up to 40 are possible. To prepare larger peptides, individual fragments are first produced and purified, and then combined to the final molecule by liquid phase synthesis. Thus, for the production of Roche's anti-AIDS drug Fuzeon (enfuvirtide), three fragments of 10–12 amino acids are first made by solid-phase synthesis and then linked together by liquid-phase synthesis. The preparation of the whole 35 amino acid peptide requires more than 130 individual steps. Microreactor Technology (MRT), used for process intensification, is a relatively new tool that is being developed at several universities, as well as fine chemical companies, such as Bayer Technology Services, Germany; Clariant, Switzerland; Evonik-Degussa, Germany; DSM, The Netherlands; Lonza, Switzerland; PCAS, France; and Sigma-Aldrich, US. The lattermost company produces about 50 fine chemicals up to multi-kilogram quantities in microreactors. From a technological point of view, MRT, or continuous flow reactors, represents the first breakthrough development in reactor design since the introduction of the stirred-tank reactor, which was used by Perkin & Sons when they established a factory on the banks of what was then the Grand Junction Canal in London in 1857, in order to produce mauveïne, the first-ever synthetic purple dye. For a comprehensive coverage of the subject see Micro Process Engineering. Reactions that have worked in microreactors include aromatics oxidations, diazomethane conversions, Grignards, halogenations, hydrogenations, nitrations, and Suzuki couplings.
Because of the large energy distribution, ions with similar mass/charge ratio can have very different kinetic energies and will thus experience different deflection for the same magnetic field. In practical terms one would see that ions with the same mass/charge ratio focus at different points in space. However, in a mass-spectrometer one wants ions with the same mass/charge ratio to focus at the same point, e.g. where the detector is located. In order to overcome these limitations, commercial MC-ICP-MS are double-focusing instruments. In a double-focusing mass-spectrometer ions are focused due to kinetic energy by the ESA (electro-static-analyzer) and kinetic energy + mass/charge (momentum) in the magnetic field. Magnet and ESA are carefully chosen to match the energy focusing properties of one another and are arranged so that the direction of energy focusing is in opposite directions. To simplify, two components have an energy focus term, when arranged properly, the energy term cancels out and ions with the same mass/charge ratio focus at the same point in space. Double-focusing does not reduce the kinetic energy distribution and different kinetic energies are not filtered or homogenized. Double-focusing works for single as well as multi-collector instruments. In single collector instruments ESA and magnet can be arranged in either forward geometry (first ESA then magnet) or reversed geometry (magnet first then ESA), as only point-to-point focusing is required.
With the advent of digital inverter compressors, the energy consumption is even further reduced than a single-speed induction motor compressor, and thus contributes far less in the way of greenhouse gases. The energy consumption of a refrigerator is also dependent on the type of refrigeration being done. For instance, Inverter Refrigerators consume comparatively less energy than a typical non-inverter refrigerator. In an inverter refrigerator, the compressor is used conditionally on requirement basis. For instance, an inverter refrigerator might use less energy during the winters than it does during the summers. This is because the compressor works for a shorter time than it does during the summers. Further, newer models of inverter compressor refrigerators take into account various external and internal conditions to adjust the compressor speed and thus optimize cooling and energy consumption. Most of them use at least 4 sensors which help detect variance in external temperature, internal temperature owing to opening of the refrigerator door or keeping new food inside; humidity and usage patterns. Depending on the sensor inputs, the compressor adjusts its speed. For example, if door is opened or new food is kept, the sensor detects an increase in temperature inside the cabin and signals the compressor to increase its speed till a pre-determined temperature is attained. After which, the compressor runs at a minimum speed to just maintain the internal temperature. The compressor typically runs between 1200 and 4500 rpm.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.